Terapet SA, RaySearch Laboratories AB, Uppsala University and Skandion Clinic Secure Eurostars Funding to Advance In-Vivo Verification and Adaptive Proton Therapy

Geneva, Switzerland, January 2026 – Terapet SA, a Geneva-based MedTech spin-off from CERN developing advanced medical imaging technologies for nuclear medicine and particle therapy, announces the award of a new Eurostars grant supporting its latest innovation project, TheraVivo – Establishing State-of-the-Art Standards for In-Vivo Verification and Adaptive Treatment Planning in Proton Therapy.

The TheraVivo project brings together a world-class consortium of industrial and clinical leaders to address a critical limitation in proton therapy today: the lack of fast, clinically standardised in-vivo verification of delivered dose.

By integrating PET-based in-vivo monitoring with treatment planning, TheraVivo aims to contribute to the development of future clinical and technical standards that support the evolution of adaptive proton therapy.

The total project investment is €2.25 million over 24 months, including €1 million in Eurostars funding from the European Commission.

A consortium bridging hardware, software and clinical validation

TheraVivo is coordinated by Terapet SA (Switzerland) and brings together:

• RaySearch Laboratories AB (Sweden) – A leading provider of radiotherapy software and developer of RayStation®, the world’s most widely used treatment planning system for particle therapy.
• Uppsala University (Sweden) – internationally recognised for academic excellence in medical physics and leading academic expertise in activation and biological washout modelling
• Skandion Clinic (Sweden) – Sweden’s national proton therapy centre and a key European clinical reference site for advanced particle therapy

Within the project, Terapet will develop Qualyscan MD, a clinically oriented medical device for in-vivo verification in proton therapy, building on its existing Qualyscan technology platform. In parallel, RaySearch will implement in-beam PET capabilities in RayStation®, enabling the interpretation and use of PET data for range verification and adaptive workflows.

These developments are conducted within a research and development framework focused on defining future clinical procedures for in-vivo verification and adaptive proton therapy. The functionality explored within TheraVivo is outside the scope of currently CE-marked product features. Any future regulatory certification processes, including CE marking, will be addressed separately.

From measurement to adaptive planning: enabling the next clinical standard

By integrating PET monitoring data directly into the treatment planning process, TheraVivo aims to provide proton therapy centres with an integrated clinical tool to better manage uncertainties and safety margins while enhancing overall treatment quality.

The project will deliver:

• An integrated hardware and software solution for in-vivo verification
• Standardised clinical workflows and implementation protocols
• Modelling of biological washout and activation dynamics to support robust interpretation of PET data
• Clinical validation at Skandion Clinic, supporting future regulatory pathways

Statements from the consortium representatives

“TheraVivo is an important step toward making in-vivo verification a real clinical standard in proton therapy. By combining Terapet’s hardware with RaySearch’s market-leading planning platform and validating the full workflow at a national clinical reference site, we are building the foundations for adaptive proton therapy as the next benchmark in precision radiotherapy,” said Dr. Christina Vallgren, CEO of Terapet SA.

“Integrating near-real-time treatment feedback into the planning process is essential for the future of high-precision adaptive proton therapy. Through TheraVivo, RaySearch will explore PET-based verification functionality, ultimately giving clinicians new tools to confirm and optimise particle therapy delivery with unprecedented confidence,” added Dr. Erik Traneus, Senior Researcher at RaySearch Laboratories AB.

“Clinical implementation and standardisation are key to making in-vivo verification usable in routine proton therapy. With TheraVivo, we aim to establish a robust, clinically validated workflow that can be adopted across centres, ultimately supporting adaptive proton therapy with greater confidence and improved patient safety,” said Prof. Alexandru Dasu, Professor at Uppsala University and Head of Research and Development at The Skandion Clinic.

About the Consortium Partners